Buchumschlag

Interaction potential of the multitargeted receptor tyrosine kinase inhibitor dovitinib with drug transporters and drug metabolising enzymes assessed in vitro

Dovitinib (TKI-258) is under development for the treatment of diverse cancer entities. No published information on its pharmacokinetic drug interaction potential is available. Thus, we assessed its interaction with important drug metabolising enzymes and drug transporters and its efficacy in multidr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Weiß, Johanna (VerfasserIn) , Theile, Dirk (VerfasserIn) , Dvorak, Zdenek (VerfasserIn) , Haefeli, Walter E. (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 16 December 2014
In: Pharmaceutics
Year: 2014, Jahrgang: 6, Heft: 4, Pages: 632-650
ISSN:1999-4923
DOI:10.3390/pharmaceutics6040632
Online-Zugang:Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.3390/pharmaceutics6040632
Verlag, lizenzpflichtig, Volltext: https://www.mdpi.com/1999-4923/6/4/632
Volltext
Verfasserangaben:Johanna Weiss, Dirk Theile, Zdenek Dvorak and Walter Emil Haefeli
Beschreibung
Zusammenfassung:Dovitinib (TKI-258) is under development for the treatment of diverse cancer entities. No published information on its pharmacokinetic drug interaction potential is available. Thus, we assessed its interaction with important drug metabolising enzymes and drug transporters and its efficacy in multidrug resistant cells in vitro.
Beschreibung:Gesehen am 16.10.2020
Beschreibung:Online Resource
ISSN:1999-4923
DOI:10.3390/pharmaceutics6040632

Ähnliche Einträge